Abstract IgM exists as both a monomer on the surface of B cells and a pentamer secreted by plasma cells. Both preimmune "natural" and antigen-induced "immune" IgM antibodies are important for protective immunity and for immune regulation of autoimmune processes by recognizing pathogens and self-antigens. Effector proteins interacting with the Fc portion of IgM, such as complement and complement receptors, have thus far been proposed but fail to fully account for the IgM-mediated protection and regulation. A major reason for this deficit in our understanding of IgM function seems to be lack of data on a long elusive Fc receptor for IgM (FcμR). We have recently identified a bona fide FcμR in both humans and mice. In this article we briefly review what we have learned so far about FcμR.
Introduction
Antibody is composed of a pair of heavy and light chains and has two biological activities: one is antigen binding via the Nterminal variable regions and the other is the effector functions mediated by the C-terminal constant regions of its heavy chains such as interaction with Fc receptors (FcRs). FcRs for IgG (FcγRI to FcγRIV), IgE (FcεRI) or IgA (FcαR) have been characterized extensively at both protein and DNA levels [1] [2] [3] [4] , but FcR for IgM (FcμR) has been defied its genetic identification, although its existence on various cell types (B, T, NK and myeloid cells) was suggested in both humans and rodents more than four decades ago (see Ref. 5) . In this article we describe FcμR, the newest member of the classical FcR family [5] , in terms of its brief history, structural aspects, cellular distribution including some new data, and potential functions. Human FcμR is mostly emphasized, but the recent findings on Fcmr-deficient mice [6] are also briefly described.
FcμR cDNA Cloning
The initial series of studies on FcμR dealt with helper function of FcμR-bearing T cells, called Tμ cells, in pokeweed mitogen-induced polyclonal B cell responses in humans as reported by many different investigators in the 1970's [7] . When monoclonal antibodies (mAbs) specific for CD4 or CD8 became available, flow cytometric analysis of Tμ cells, which were separated by rosette formation with ox erythrocytes pre-coated with IgM antibodies, revealed that the Tμ cell fraction contained both CD4 T and CD8 T cell subsets [8] . The second wave of FcμR studies was the biochemical characterization of an activation antigen on B cells recognized by BAC-1 mAb of IgM isotype [9] [10] [11] . Sheila Sanders, then a post-doctoral fellow in the laboratory of Max Cooper, identified a sialoglycoprotein with a M r of 60 kDa that precipitated with IgM mAbs irrespective of their antigen-binding specificity from lysates of surface iodinated, phorbol myristate acetate (PMA)-activated, but not resting, blood B cells. Since the 60 kDa glycoprotein was not precipitated by mAbs of other isotypes with the same antigen-binding specificity, it was suggested as an IgM-binding protein [9] . The 60 kDa IgM binding protein was also identified on freshly-prepared chronic lymphocytic leukemia (CLL) B cells and PMA-activated, human pre-B leukemia cell line 697 [9, 10] . The IgM binding by PMA-activated, normal blood B or 697 pre-B cells as well as by CLL B cells could be demonstrated by flow cytometric analysis using highly purified IgM preparations [9, 10] . A similar 60 kDa IgM binding protein was also identified on T cells after short-term culture in IgM-free media with protease inhibitors [11] .
Given these precedents and the successful establishment of retroviral cDNA library-based functional cloning by Eiji Takayama in my laboratory, Ikuko Torii generated two cDNA libraries from human B-lineage cells, one from CLL B cells and the other from PMA-activated 697 pre-B cells, ligated them into a retroviral expression vector and introduced them into mouse thymoma line BW5147 which lacks IgM binding. Transduced cells exhibiting IgM binding in each library were enriched thrice by magnetic-activated cell sorting and then by fluorescence-activated cell sorting before subcloning by limiting dilution. Nucleotide sequence analyses of the insert cDNA responsible for IgM binding from both cDNA libraries revealed an identical 1,173-bp open reading frame which was predicted to encode a 390-aa type I membrane protein [5] . After cleavage of a 17-aa signal peptide, the predicted FcμR consists of a 107-aa V-set Ig-like domain responsible for IgM binding, an additional 127-aa extracellular region with no known domain structure (called "stalk" region in this paper), a 21-aa transmembrane segment containing a charged His residue, and a relatively long (118-aa) cytoplasmic tail (see Fig. 1 ). There are no N-linked glycosylation motifs in the extracellular region, consistent with our previous biochemical characterization of the FcμR [10] . Vire et al. have recently reported that there are several O-linked glycosylation sites in the stalk region and some of the potential Ser and Thr residues are indeed responsible for O-linked glycosylation as determined by point mutational analyses [12] . The core peptide is predicted to have a M r of~41 kDa and an isoelectric point (pI) of~9.9. FCMR is a single copy gene located on chromosome 1q32.2, adjacent to two other IgM-binding receptor genes, polymeric Ig receptor (PIGR) and FcR for IgA and IgM (FCAMR) [5] (Fig. 2) . [13] . The avidity of IgM/ FcμR binding was found to be strikingly high,~10 nM by Scatchard plot analysis with an assumption of a 1:1 stoichiometry of pentameric IgM ligand to FcμR [5] . Although Nguyen et al. [14] have claimed the lack of IgM-ligand binding with their transductant transiently expressing Toso, an initial designation of FcμR [15] (see below), the results from subsequent studies by us [16] and others [12, 17] [18] . As shown in Fig. 3 , in addition to a disulfide bond linking the two β sheets (B and F strands), a second disulfide bond linking the C and C′ strands is also conserved in all three receptors. Many other residues shown in yellow are also completely conserved, but several other residues shown in red are conserved in pIgR and Fcα/μR, and not in FcμR. A major difference between FcμR and the other two receptors is in the complementarity-determining region 1 (CDR1), which consists of 9 aa for pIgR and Fcα/ μR, whereas FcμR has 5 aa and a non-charged residue (Met, Leu, or Thr) at the position corresponding to Arg that is predicted to interact directly with polymeric IgA with pIgR [18] . These findings suggest a structural basis for the distinct mode of IgM interaction with FcμR versus pIgR and Fcα/μR. FcμR was resolved as an~60 kDa sialoglycoprotein on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and was more efficiently identified by receptor-specific mAbs than IgM ligands [5] . Since the predicted core peptide is~41 kDa, one third of the M r of FcμR is found to constitute carbohydrate moiety. While the pI is predicted as~9.9, the~60 kDa FcμR was resolved into a spot with a pI of~5 by two-dimensional gel electrophoresis, suggesting that mature FcμR contains many sialic acids, consistent with our previous findings [10] . An additional minor protein of~40 kDa (p40) was often co-precipitated with the FcμR, but it remains unclear whether p40 represents another membrane protein non-covalently associated with FcμR or an unglycosylated form of FcμR [5] . Sequential precipitation analysis with receptor-specific mAbs and IgMligands revealed that pre-incubation of membrane lysates of FcμR + cells with mAbs completely removed the IgMreactive 60 kDa protein, whereas the reverse did not efficiently remove the mAb-reactive 60 kDa protein, suggesting that mAbs are better than IgM ligands in the detection of FcμR.
Structural Aspects
In our earlier biochemical analysis, FcμR on PMAactivated 697 pre-B cells could be attached to the plasma membrane via a glycosylphosphatidylinositol (GPI) linkage, but the structure predicted by the cDNA is a transmembrane protein [10] . [Extensive search for a cDNA encoding a potential GPI-linked form of FcμR failed.] Satoshi Oka reexamined this issue using a highly purified GPI-specific phospholipase C (GPI-PLC) and found that after GPI-PLC treatment, the surface levels of FcμR and CD19 on PMA-activated 697 pre-B cells were unchanged, whereas the expression of GPIanchored CD73 was reduced by~50 %, indicating an authentic transmembrane protein of FcμR [5] . However, it is difficult to explain some biochemical data in our earlier studies where GPI-PLC was not used. Namely, when cell-surface iodinated, PMA-activated 697 pre-B cells were incubated at 37°C even without GPI-PLC, significant amounts of the~60 kDa IgMbinding protein was also released into the medium [10] . Furthermore, the~60 kDa IgM-binding protein was unequivocally precipitated from the culture supernatants of metabolically labeled, PMA-activated 697 pre-B cells by IgMcoupled beads [10] . Taken together, these findings highly suggest the possibility that FcμR is released as small vesicles or exsosomes from the plasma membrane upon activation.
Another intriguing issue in FcR fields is the inducibility of FcRs by exposure to the corresponding Ig ligands, although such Ig-binding molecules have defied biochemical characterization. For example, IgA-binding capacity of mouse T cells was induced by exposure to IgA in vivo and in vitro [19] ; however, this binding must be mediated by a non-FcαR/ CD89 molecule, because mice lack the human FcαR/CD89 homolog gene [20, 21] . Similarly, both mouse and human IgM induced the IgM receptor on 697 pre-B cells in a dosedependent manner without a plateau, and IgM receptor expression was maximal within 30 min after exposure, whereas longer exposure to PMA was required for maximal IgM binding [10] . The upregulation of IgM receptor was dependent on the continuous presence of the ligand, as removal of IgM from the culture resulted in a time-dependent decline of IgM receptor expression by 697 pre-B cells. Yoshiki Kubagawa reexamined this dichotomy and concluded that such ligand-induced IgM receptor on 697 pre-B cells was not the FcμR as determined by receptor-specific mAbs (Fig. 4) . It is thus suggested that another molecule such as certain lectins is responsible for the above IgM binding. In this regard, CD22 (siglec-2), a B cell membrane-bound lectin recognizing glycan ligands containing α2,6-linked sialic acid, was recently shown to interact with glycan ligands on soluble IgM/antigen complexes, thereby negatively regulating BCR signaling similar to FcγRIIB [22, 23] . Other IgM-binding proteins have also been demonstrated in other cell types. For example, tripartite motif-containing protein 21 (TRIM21)/ Ro52 binds antibody-opsonized pathogens and targets them to proteasomal degradation in phagocytes, and thus, the TRIM21/Ro52 behaves as a cytosolic Fc receptor for IgG and IgM [24, 25] (see the article of Leo James in this volume).
Apoptosis inhibitor of macrophage (AIM)/Spα, a member of the group B scavenger receptor cysteine-rich superfamily, is a soluble protein of~45 kDa produced by macrophages (Mφs) and is known to bind serum IgM but not IgG or IgA, in addition to support the survival of Mφs [26] [27] [28] . Recent data from analysis of Aim-deficient mice suggest that AIM plays an important role in obesity-associated natural IgM autoantibody process in Fcα/μR-bearing follicular dendritic cells (FDCs) [29] .
4) Conserved Tyr and Ser residues:
The following common feature is observed with many paired receptors having a similar extracellular region but transmitting opposite signal potentials, such as FcγRs and NK cell receptors. One type has a short cytoplasmic tail but a charged aa in the transmembrane segment through which another transmembrane protein carrying immunoreceptor Tyr-based activation motifs (ITAMs) non-covalently associates with. The other type has a regular hydrophobic transmembrane and a long cytoplasmic tail containing immunoreceptor Tyr-based inhibitory motifs (ITIMs). In this regard, FcμR is unique, because it has a charged His residue in the transmembrane segment and a long cytoplasmic tail containing conserved Tyr and Ser residues, when compared with FcμRs from six different species and FcμR of human (NP_005440), mouse (NP_081252), and rat (Q5M871). Crystallographically determined secondary structure elements and the topology diagram of human pIgR, which are determined by Hamburger et al. [18] , are shown above the sequences and in a right lower corner, respectively. The β strands A, B, E, and D are shown in blue, β strands C″, C′, C, F, G, and A′ are in green, and three CDR loops (including the α helix within CDR1) are red. The permission to incorporate the structural data has been obtained from Dr. Pamela Bjorkman (Fig. 5 ). This suggests that FcμR has a dual signaling ability: one from a potential adaptor protein noncovalently associating with FcμR via the His residue, similar to the association of FcR common γ chain with FcγRI [1] , and the other from its own Tyr and/or Ser residues in the cytoplasmic tail. [30] [31] [32] [33] [34] [35] , but the C-terminal Tyr matches the recently described Ig tail Tyr (ITT) motif (DYxN) in IgG and IgE isotypes [36] . The two carboxyl terminal Tyr residues were found to be involved in the FcμR-mediated endocytosis in CLL B cells [12] . It was also shown that FcμR ligation on NK cell transductants or primary NK cells with IgM immune complexes induced phosphorylation of PLCγ and ERK1/2 [17] .
Cellular Distribution of FcμR
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of various tissues and a panel of representative cell lines revealed that FcμR transcripts were restricted to hematopoietic and lymphoid tissues, including the bone marrow, blood, spleen, tonsils and appendix [5] . FcμR transcripts were detected in both CD4 + and CD8 + T cells and in all subsets of tonsillar B cells, although the transcript levels appeared higher in the follicular and memory B cells than in the pre-germinal and germinal center B cells, consistent with data reported by others [37] . [5] .
Satoshi Oka examined the cell surface expression of FcμR by flow cytometric analysis using a panel of ten receptor specific mAbs and IgM ligands. Unlike earlier findings using rosette formation with IgM-coated erythrocytes, FcμR expression in humans is restricted to adaptive immune cells, both B and T lymphocytes, but not to innate immune cells [5] . The lack of FcμR expression by myeloid cells was also the case when they were activated with various stimuli including PMA/ionomycin, LPS, mitogens and several cytokines. Neither erythrocytes nor platelets expressed FcμR. NK cells were the only known exception for FcμR expression by cells other than B and T cells in humans [5, 17] , but are now implicated to have features of both adaptive and innate cells [39] . FcμR is thus the only FcR constitutively expressed on T cells, which are generally negative for the expression of other FcRs. For B cells, FcμR is the only IgM-binding receptor expressed; although Fcα/μR was initially shown to be expressed by B cells [40] , our subsequent analyses revealed that the major cell type expressing Fcα/μR is a FDC in both humans and mice [41] . Clearly, mAb reactivity was a more sensitive assay for the detection of FcμR than ligand binding [5] . Notably, preincubation of blood MNCs with IgM-free media enhanced FcμR expression especially by T cells, consistent with our previous findings [11] . Intriguingly, this enhancement was more evident in cell preparations from tonsils and spleen than from blood. Freshly prepared tonsillar MNCs, including both B and T cells, had no reactivity with either anti-FcμR mAbs or IgM ligands, but after pre-incubation, there was clear-cut expression of FcμR on the surface of CD19 + B, CD4 + T and CD8 + T cells [5] . Since many other cell-surface antigens were easily detectable in those freshly isolated preparations, this in vivo down-modulation of FcμR was not due to an artifact of tissue manipulation, but rather to certain consequences. One possibility is that the IgM concentration in the interstitial spaces of such intact tissues, which has never been assessed, may be much higher than in blood (>~2 mg/ml). Alternatively, the tissue microenvironment (e.g., proteases) or cellular activation status may cleave the cell surface FcμR or may release FcμR-containing small membrane vesicles (or exosomes) from the plasma membrane.
In addition to the common classification of memory (CD27 Fig. 6b upper) ; the results are consistent with RT-PCR and microarray data by us and others [5, 37] . Among the memory B cell compartment, a similar trend of FcμR levels seen in the blood was also observed: resting > activated memory or tissue-like memory (Fig. 6b lower) . (Fig. 7b) . As to FcμR expression during ontogeny, Naonori Nishida, Toshio Miyawaki and Kazuhito Honjo compared the expression of FcμR between cord and adult blood MNCs and found that FcμR levels on B cells were significantly lower in cord blood than adult blood, whereas FcμR levels on other cell types (CD4 T, CD8 T, Treg, and NK cells) were comparable.
In adult bone marrow, a small subpopulation (~20 %) of the pro-B/pre-B cells (CD19 + surface IgM − ) expressed low levels of FcμR on their cell surface, whereas~40 % of the B cells expressed slightly higher levels of FcμR, indicating that FcμR expression begins at the pro-B/pre-B cell stage in B-lineage differentiation. Collectively, these findings indicate that in striking contrast to FcRs for switched Ig isotypes, human FcμR is predominantly expressed by the adaptive immune cells and that the cell surface levels of FcμR are sensitive to [5] . CLL patients also had high serum titers of FcμR compared with healthy donors as determined by sandwich ELISA using two different receptor-specific mAbs. Serum FcμR levels correlated well with circulating lymphocyte numbers but not with the IGHV mutation status or Rai stage. The serum FcμR was resolved as an~40 kDa protein, distinct from the cell surface FcμR of~60 kDa, was produced by both CLL B and non-CLL B cells and shown by proteomic analysis to be a soluble form of the receptor encoded by an alternatively spliced FcμR transcript. The molecular basis for such soluble FcμR production in CLL patients, however, remains unclear as does the clinical effect of such levels as a decoy receptor on the immune responses of CLL patients. These findings indicate enhanced levels of both membranebound and soluble forms of FcμR in CLL patients [51] .
Recent seminal findings from the laboratory of Hassan Jumaa have suggested that in contrast to other B cell malignancies, CLL-derived BCR ligates each other via interactions between the Ig heavy chain CDR3 of one BCR and an intrinsic motif (WVRQxPG; bold fonts indicate critical aa residues) in the framework region 2 of another, thereby generating antigen-independent cell-autonomous signaling [52] . This antigen-independent self-ligation of BCR on CLL cells is consistent with the well-known findings of reduced levels of cell surface IgM and IgD on CLL cells and may induce upregulation of cell surface FcμR as observed with ex vivo BCR cross-linkage with anti-μ mAbs. Many CLL patients contain significant amounts of CLL-derived IgM in their sera as determined by using CLL BCR idiotype-specific reagents [53] [54] [55] . As CLL-derived IgM often reacts with selfantigens [56] , the following proposed scenario would be conceivable. Subpopulations of CLL B cells undergo differentiation into plasma cells that secrete IgM. Secreted IgM in turn binds self-antigens of either soluble or membrane-associated form, and the resultant soluble IgM immune complexes co-ligate BCR and FcμR or the Fc portion of IgM bound to self-antigens on CLL cells binds FcμR in cis, thereby providing a survival signal to CLL B cells via FcμR (Fig. 8) . Fig. 7 FcμR expression by T cell subsets in blood and tonsils.
CD8 T
MNCs from blood (a) and tonsils (b) were similarly stained as in Fig. 6 [57] . Strangely, Ly6G
− bone marrow cells which should contain a significant number of FcμR-expressing B cells, were negative with their B68 mAb [57] . In this regard, we reexamined extensively and found that none of our mAbs reacted specifically with the cell surface of these phagocytes and that FcμR transcripts were clearly detectable in B-lineage cells but not in the double sorted Ly6G + granulocytes or in Rag1-deficient splenocytes, which were devoid of B and T cells but contained abundant granulocytes and Mφs, even after 35 cycles of amplification [6, 58] . Thus, these findings conclusively demonstrate at both protein and RNA levels that FcμR is not expressed by myeloid cells. This conclusion is very important when we consider the role of FcμR in bacterial infection models as described in ref. 57. 3) FcμR-deficiency: Fcmr KO mice have been independently generated by two laboratories, our collaborator Hiroshi Ohno at RIKEN in Yokohama and Tak Mak at Ontario Cancer Institute in Toronto, and recently have been characterized by four different groups of investigators with clear differences in the reported phenotypes [6, 57, 59, 60] . Although the basis for these discrepancies requires further investigations, it might be due in part to: (i) different strategies for gene targeting (i.e., deletion of exon 2 to 4 [6, 59] versus exon 2 to 8 [57, 60] and/or the absence [6, 59] versus presence of the Neo gene [57, 60] in the mouse genome) as well as the extent of the 129-origin DNA around the Fcmr gene remaining after backcrossing onto C57BL/6, (ii) investigators' concepts of the function of FcμR/Toso as an IgM binding protein versus an anti-apoptotic protein, and/or (iii) other factors (e.g., mouse ages, environments including intestinal microbiota or reagents used). Nevertheless, the abnormal phenotypes commonly observed (in at least two laboratories) in Fcmr KO mice are: (i) increase in pre-immune serum IgM [6, 59] , (ii) alterations in B cell subpopulations [6, 59, 60] , (iii) dysregulation of humoral immune responses [6, 59, 60] , (iv) impairment of B cell proliferation upon ligation of BCR in vitro [59, 60] , and (v) predisposition to autoantibody production [6, 59, 60] .
Notably, many abnormalities in Fcmr KO mice mirror those observed in μs exon-deleted mice (μs −/− ) that are unable to secrete IgM but are able to express surface IgM and other Ig isotypes on B cells and to secrete all other classes of Igs [61] . Studies with these μs −/− mice have reinforced the importance of both pre-immune "natural" and antigen-induced "immune" IgM antibodies in protection against infectious and autoimmune diseases [62, 63] . Such μs −/− mutant mice cannot 
